Immutep (ASX:IMM) completed the enrolment target of 40 patients for the EFTISARC-NEO second phase trial in Warsaw, Poland, according to a Wednesday filing with the Australian bourse.
The EFTISARC-NEO trial is evaluating the immunotherapy eftilagimod alpha in combination with radiotherapy Keytruda in the neoadjuvant setting for patients with resectable soft tissue sarcoma, the filing said.
It earlier reported that the combination achieved a greater than three-fold increase in tumor hyalinization/fibrosis at the time of surgical resection among 21 patients available for primary endpoint assessment.
Data updates from the trial are expected in 2025, per the filing.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。